Scancell Holdings Plc, have announced the publication, on line, of a full paper in Cancer Research describing the rationale behind the Company's Moditope® platform and the experimental results that support it. Cancer Research is the official journal of the American Association for Cancer Research and is one of the world's foremost peer-reviewed journals in the field of oncology.
Prof Lindy Durrant, Joint CEO of Scancell, said: "The publication of this paper on the science behind Moditope® in such a prestigious and widely read cancer journal is not only a great achievement for the research team at Scancell, it provides a ringing endorsement from the scientific community for this completely innovative approach to the treatment of cancer. This important paper lays out the foundation, rationale and experimental basis for the Moditope® platform and its potential to generate effective cancer vaccines."
The lead product from the Moditope® platform, Modi-1, is progressing through pre-clinical development with first in man studies targeted in triple negative breast cancer and ovarian cancer patients.
Article: Citrullinated vimentin presented on MHC-II in tumor cells is a target for CD4+ T cell-mediated antitumor immunity, Victoria A Brentville, Rachael L Metheringham, Barbara Gunn, Peter Symonds, Ian Daniels, Mohamed Gijon, Katherine Cook, Wei Xue, Lindy G Durrant, Cancer Research, doi: 10.1158/0008-5472.CAN-15-1085, published online 30 December 2015.